Clinical-Trial
Clinical-Trial funding pages collect matching grants, scholarships, benefits, fellowships, and other programs from the FindMyMoney.App directory. Use this page to compare current opportunities, then verify deadlines and eligibility on the official source before applying.
Emerging Global Leader Award (K43 Independent Clinical Trial Required): PAR-24-295
Fogarty International Center career-development award for LMIC junior faculty who lead their own clinical trial-based research project with U.S. mentorship to build independent global-health research careers.
NIH R01 Clinical Trial Required Parent NOFO (PA-25-305): 2026/2027 Guide
Parent NIH Research Project Grant (R01) mechanism requiring a clinical trial, with recurring NIH submission cycles through mid-2028 and 2027 planning-relevant deadlines.
PAR-24-211: NHLBI Career Transition Award (K22 Clinical Trial Required)
NIH Career Development K22 program for intramural NHLBI postdocs and research trainees transitioning to independent extramural investigators, with two required review/training phases and a full-project duration of up to five years.
PAR-25-270: NCCIH Natural Product Early Phase Clinical Trial Award (R33)
NIH NOFO for R33 early-phase natural-product clinical trials focused on target-engagement evidence before larger efficacy studies, with a direct-cost cap of $1,050,000 over up to 3 years and strict clinical-trial-only eligibility.
PAR-25-449: Mind and Body Interventions to Restore Whole Person Health via Emotional Well-Being Mechanisms (R61/R33 Clinical Trial Required)
A NCCIH phased NIH parent R61/R33 NOFO supporting mind-body mechanistic clinical trials with strong preliminary data, explicit feasibility milestones, and continuation criteria, with recurring submission cycles into the 2027 review cycle.
PAR-26-001: Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for Alcohol, Tobacco, and Other Drugs (ATOD) Use and Misuse in Adult Populations that Experience Health Disparities
A recurring NIH parent announcement for NIH-defined clinical trial R01 projects that test and scale SBIRT/P interventions for ATOD use and misuse among adults affected by health disparities.
RFA-DC-25-003: Cooperative Agreement for In Vivo High-Resolution Inner Ear Imaging (U01, Clinical Trial Required)
NIH/NIDCD funding for investigator-initiated high-risk clinical trials that advance non-invasive in vivo imaging of the inner ear and support translation of imaging technologies into clinical care.
RFA-DC-25-005: In Vivo High-Resolution Imaging for Inner Ear Visualization (R01, Clinical Trial Optional)
This NIH NIDCD RFA funds projects that develop higher-resolution structural or functional imaging for the living human inner ear, with up to $500,000 direct costs per year and FY 2026/2027 allocations.
RFA-DK-26-315: Advancing Research on Digital Health Technology for Type 2 Diabetes (R01)
NIH RFA-DK-26-315 is a clinical-trial R01 opportunity for U.S. institutions to test digital health approaches to improve type 2 diabetes management, with submission cycles in 2026 and 2027 and a strict non-responsiveness rule against tool-building and T1D-only projects.
RFA-FD-25-020: Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01)
FDA’s Office of Orphan Products Development supports clinical trials for rare disease products through OOPD RFA-FD-25-020, including recurring 2026 and 2027 due dates with up to $650,000 annually in base project support.